10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
MERCK & CO., INC. | |||
Ticker: MRK Fiscal Year: 2021 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2021 10-K (Filed: Feb 25, 2022) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | |
| Cash Flows from Operating Activities of Continuing Operations | |||
| Net income from continuing operations | $ 12,358 | 4,523 | 5,606 |
| Adjustments to reconcile net income from continuing operations to net cash provided by operating activities of continuing operations: | |||
| Amortization | 1,636 | 1,817 | 1,695 |
| Depreciation | 1,578 | 1,669 | 1,615 |
| Intangible asset impairment charges | 302 | 1,718 | 1,040 |
| Income from investments in equity securities, net | (1,940) | (1,338) | (170) |
| Charge for the acquisition of Pandion Therapeutics, Inc. | 1,556 | 0 | 0 |
| Charge for the acquisition of VelosBio Inc. | 0 | 2,660 | 0 |
| Charge for the acquisition of Peloton Therapeutics, Inc. | 0 | 0 | 993 |
| Deferred income taxes | 187 | (566) | (560) |
| Share-based compensation | 479 | 441 | 388 |
| Other | 805 | 1,294 | 354 |
| Net changes in assets and liabilities: | |||
| Accounts receivable | (2,033) | (1,002) | 92 |
| Inventories | (674) | (895) | (473) |
| Trade accounts payable | 405 | 684 | 443 |
| Accrued and other current liabilities | 277 | (1,152) | 413 |
| Income taxes payable | (540) | 814 | (1,889) |
| Noncurrent liabilities | 484 | (617) | (733) |
| Other | (1,758) | (2,433) | 70 |
| Net Cash Provided by Operating Activities of Continuing Operations | 13,122 | 7,617 | 8,884 |
| Cash Flows from Investing Activities of Continuing Operations | |||
| Capital expenditures | (4,448) | (4,429) | (3,369) |
| Purchase of Seagen Inc. common stock | 0 | (1,000) | 0 |
| Purchases of securities and other investments | (1) | (95) | (3,202) |
| Proceeds from sales of securities and other investments | 1,026 | 2,812 | 8,622 |
| Acquisition of Acceleron Pharma Inc., net of cash acquired | (11,174) | 0 | 0 |
| Acquisition of Pandion Therapeutics, Inc., net of cash acquired | (1,554) | 0 | 0 |
| Acquisition of VelosBio Inc., net of cash acquired | 0 | (2,696) | 0 |
| Acquisition of ArQule, Inc., net of cash acquired | 0 | (2,545) | 0 |
| Acquisition of Antelliq Corporation, net of cash acquired | 0 | 0 | (3,620) |
| Acquisition of Peloton Therapeutics, Inc., net of cash acquired | 0 | 0 | (1,040) |
| Other acquisitions, net of cash acquired | (179) | (1,365) | (294) |
| Other | (91) | 125 | 374 |
| Net Cash Used in Investing Activities of Continuing Operations | (16,421) | (9,193) | (2,529) |
| Cash Flows from Financing Activities of Continuing Operations | |||
| Net change in short-term borrowings | (3,986) | 2,549 | (3,710) |
| Payments on debt | (2,319) | (1,957) | 0 |
| Proceeds from issuance of debt | 7,936 | 4,419 | 4,958 |
| Distribution from Organon & Co. | 9,000 | 0 | 0 |
| Purchases of treasury stock | (840) | (1,281) | (4,780) |
| Dividends paid to stockholders | (6,610) | (6,215) | (5,695) |
| Proceeds from exercise of stock options | 202 | 89 | 361 |
| Other | (286) | (436) | 5 |
| Net Cash Provided by (Used in) Financing Activities of Continuing Operations | 3,097 | (2,832) | (8,861) |
| Discontinued Operations | |||
| Net cash provided by operating activities | 987 | 2,636 | 4,556 |
| Net cash used in investing activities | (134) | (250) | (100) |
| Net cash used in financing activities | (504) | 0 | 0 |
| Net Cash Flows Provided by Discontinued Operations | 349 | 2,386 | 4,456 |
| Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash | (133) | 253 | 17 |
| Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash | 14 | (1,769) | 1,967 |
| Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes $103 of restricted cash at January 1, 2021 included in Other Assets - see Note 7) | 8,153 | 9,934 | |
| Less: Cash and cash equivalents related to discontinued operations | 0 | 12 | 0 |
| Cash, Cash Equivalents and Restricted Cash at End of Year (includes $71 of restricted cash at December 31, 2021 included in Other Assets - see Note 7) | 8,167 | 8,153 | 9,934 |
| External Links | |
| MERCK & CO., INC. (MRK) Fiscal Year 2021 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |